Search

Displaying results 8231 - 8240 of 9710 in total
  1. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  2. Drug

    Tetrodotoxin

    go.drugbank.com/drugs/DB05232
    Investigational

    An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction. Tetrodotox...

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    LGD2941

    go.drugbank.com/drugs/DB05234
    Experimental

    LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.

  4. Drug

    ReN001

    go.drugbank.com/drugs/DB05236
    Investigational

    ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans

  5. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...

    Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  6. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.

  7. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    the RNAi response against a targeted disease causing gene. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

  8. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  9. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune

    Synonyms: (T,G)-A-L
  10. Drug

    Oxypurinol

    go.drugbank.com/drugs/DB05262
    Investigational

    Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.